查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016888

转染试剂及设备市场：全球市场按产品类型、细胞类型、应用和最终用户分類的预测，2026-2032年

Transfection Reagents & Equipment Market by Product Type, Cell Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，转染试剂和设备市场价值将达到 14.9 亿美元，到 2026 年将成长到 16 亿美元，到 2032 年将达到 24.3 亿美元，复合年增长率为 7.18%。

主要市场统计数据
基准年 2025 14.9亿美元
预计年份：2026年 16亿美元
预测年份 2032 24.3亿美元
复合年增长率 (%) 7.18%

转染试剂和仪器的市场正经历着快速的技术和商业性变革，这主要得益于递送化学、自动化技术的进步以及基因调控研究范围的不断扩大。近年来，研究人员和采购团队已将采购重点从成本驱动型转向可重复性、扩充性和法规可追溯性。因此，供应商正大力投资于平台稳定性、检验的实验方案以及整合的软硬体解决方案，以减少不同细胞类型和实验形式之间的差异。

本导言概述了报告的主题，重点在于创新、营运韧性和终端用户需求。导言也强调了分子生物学家、工程师和生物资讯学家之间跨学科合作对产品开发週期日益增长的影响。此外，导言指出，生物製药公司对支持加速转化工作流程（例如细胞株开发和基因治疗研究）的试剂和仪器的需求不断增长。透过将这些趋势置于更广泛的研究重点和采购惯例背景下，本导言建立了贯穿整个报告的分析框架，并表明了报告旨在提供可操作的见解以支持战略决策的预期目标。

变革性的变化正在重新定义转染工作流程，包括自动化、非病毒递送技术的创新、单细胞方法以及与基因编辑平台的整合。

转染生态系统正经历一场变革性的转变，这场变革正在重塑从实验室到临床的工作流程。首先，转染工作流程的自动化和小型化降低了人为操作的差异性，实现了高通量实验，并加速了方案最佳化的迭代週期。其次，非病毒递送技术的创新，包括新一代脂质体、聚合物和物理方法，正在拓宽适用细胞类型和有效载荷的范围，从而使以往因毒性或效率低下而受限的应用成为可能。

评估美国于 2025 年征收的关税对生命科学实验室整个供应链、筹资策略和业务永续营运的累积影响。

2025年关税的实施为整个转染价值链的采购、供应商关係和成本结构带来了一系列营运和策略压力。为因应这一局面，许多实验室和机构立即调整了筹资策略，以缓解短期成本上涨，优先选择製造地多元化且能够提供本地库存缓衝的供应商。这些调整通常涉及重新谈判条款、合併订单以维持价格，以及加强与经销商的合作以确保供应的连续性。

透过对产品类型、电池类型、应用和最终用户进行关键細項分析，揭示了细微的需求驱动因素和采购行为。

基于细分市场的洞察揭示了每种产品类型、细胞类型、应用和最终用户的不同需求模式和操作要求。根据产品类型，市场细分为仪器和试剂两部分。仪器的采购越来越受到与自动化系统相容性和数据整合的影响，而试剂的评估则侧重于配方稳定性和跨平台性能。根据细胞类型，市场被细分为细菌细胞、昆虫细胞、哺乳动物细胞和植物细胞。每种细胞类型都有独特的转染灵敏度、通量要求和验证挑战，这些都会影响试剂的选择和方案的开发。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和竞争地位，为市场进入和伙伴关係策略提供了宝贵的见解。

区域趋势影响关键区域的竞争定位和打入市场策略。在美洲，生物製药研发投入的增加，以及合约研究组织 (CRO) 和先进学术研究中心的强大实力，推动了对高性能试剂和整合仪器的需求，这些试剂和仪器能够支援转化医学流程。该地区的市场参与企业通常优先考虑监管合规性、供应商透明度和能够加速临床应用的伙伴关係模式。

透过研发、伙伴关係和平台扩展，对推动转染试剂和仪器市场发展的主要企业进行策略概况和能力分析。

该领域的主要企业正透过整合研发投入、策略伙伴关係以及拓展平台功能来脱颖而出。一些企业专注于对试剂进行化学优化，以提高递送效率并降低细胞毒性，即使在难治性细胞类型中也是如此；而另一些企业则致力于整合硬体、软体和耗材，提供降低应用门槛的承包解决方案。试剂开发商与仪器製造商之间的合作日益普遍，与学术研究机构和受託研究机构(CRO) 的合作也越来越多，旨在检验不同应用情境下的工作流程。

为产业领导者提供实用建议，以加速采用、优化供应链，并在不同的转染市场区隔领域中取得价值。

产业领导者应采取一系列切实可行的措施，加速技术应用，强化供应链，并在各个细分市场中获取策略价值。首先，应投资开发检验的跨平台方案和全面的应用说明，以展示技术在关键细胞类型和应用场景中的表现。这些依证将降低技术应用门槛，并为学术机构、生物製药公司和合约研究组织 (CRO) 的采购决策提供支援。其次，应实现生产和物流地点的多元化，以降低贸易和关税风险，同时确保关键试剂和设备组件的持续供应。

调查方法详细介绍了资料来源、与相关人员的访谈、一手和二手研究的整合以及确保严谨性的分析框架。

本分析的调查方法透过整合一手访谈、二手资料整合和交叉检验的专家评审，确保了分析的严谨性和有效性。一手研究包括对顶尖学术机构、生物製药公司和合约研究组织（CRO）的实验室主任、采购经理、研发科学家和业务部门负责人进行结构化访谈。透过这些对话，我们直接了解了采购因素、绩效挑战和验证重点。

总结了相关人员在转染生态系统中所面临的策略意义、风险考量和优先行动。

总之，转染试剂和仪器的生态系统正在创新、监管预期和采购行为变化交汇融合，并不断发展演变。递送化学、自动化以及与基因编辑平台整合的技术进步，在扩大应用范围的同时，也提高了可重复性和品质保证的标准。同时，贸易趋势和不断发展的区域能力正在重塑供应链策略和商业性模式。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：转染试剂与设备市场：依产品类型划分

  • 装置
  • 试剂

第九章：转染试剂与设备市场：依细胞类型划分

  • 细菌细胞
  • 昆虫细胞
  • 哺乳动物细胞
  • 植物细胞

第十章：转染试剂与设备市场：依应用领域划分

  • 细胞株构建
  • 药物发现
  • 基因治疗研究

第十一章 转染试剂与设备市场：依最终用户划分

  • 学术研究机构
  • 生物製药公司
  • 合约研究机构

第十二章 转染试剂与设备市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 转染试剂与设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 转染试剂与设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国转染试剂与设备市场

第十六章：中国转染试剂与设备市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Altogen Biosystems
  • Applied Biological Materials, Inc.
  • Bex Co.,ltd.
  • BioVision Inc.
  • Bio-Rad Laboratories, Inc.
  • Cytiva
  • GeneCopoeia, Inc.
  • Lonza Group AG
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
Product Code: MRR-031685195779

The Transfection Reagents & Equipment Market was valued at USD 1.49 billion in 2025 and is projected to grow to USD 1.60 billion in 2026, with a CAGR of 7.18%, reaching USD 2.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.49 billion
Estimated Year [2026] USD 1.60 billion
Forecast Year [2032] USD 2.43 billion
CAGR (%) 7.18%

The transfection reagents and equipment landscape is experiencing rapid technological and commercial evolution, driven by converging advances in delivery chemistry, automation, and the expanding scope of gene-modulation research. Over the past several years, researchers and procurement teams have shifted priorities from cost-centric purchasing to an emphasis on reproducibility, scalability, and regulatory traceability. As a result, suppliers are investing heavily in platform robustness, validated protocols, and integrated hardware-software solutions that reduce variability across cell types and experimental formats.

This introduction frames the report's thematic focus on innovation, operational resilience, and end-user needs. It highlights how product development cycles are increasingly informed by cross-disciplinary collaboration between molecular biologists, engineers, and bioinformaticians. In addition, it acknowledges the heightened expectations from biopharmaceutical companies for reagents and instruments that support accelerated translational workflows, including cell line development and gene therapy research. By situating these trends within the broader context of research priorities and procurement practices, the introduction establishes the analytic lens used throughout the report and sets expectations for actionable insights that support strategic decision-making.

Transformative shifts redefining transfection workflows including automation, non-viral delivery innovations, single-cell approaches, and convergence with gene editing platforms

The transfection ecosystem is undergoing transformative shifts that are reshaping workflows from bench to clinic. First, automation and miniaturization of transfection workflows have reduced manual variability and enabled higher-throughput experimentation, which supports more rapid iterative cycles in protocol optimization. Second, non-viral delivery innovations, including next-generation lipids, polymers, and physical methods, are broadening the range of tractable cell types and payloads, enabling applications that were previously constrained by toxicity or low efficiency.

Concurrently, the widespread adoption of gene editing platforms such as CRISPR-Cas systems has created tighter integration between delivery reagents and editing toolkits, leading to bundled solutions that improve editing efficiency and reduce off-target effects. Single-cell analysis and high-content screening are also influencing reagent formulation and instrument design, requiring gentler delivery approaches and highly reproducible conditions. Moreover, regulatory and quality expectations are driving demand for reagents and equipment with robust documentation, lot-to-lot consistency, and compatibility with GMP workflows. Together, these shifts compel suppliers and end users to rethink product road maps, validation strategies, and service models to remain competitive and to accelerate translational impact.

Cumulative impact assessment of United States tariffs introduced in 2025 on supply chains, procurement strategies, and operational resilience across life science labs

The imposition of tariffs in 2025 introduced a set of operational and strategic pressures that have affected procurement, supplier relationships, and cost structures across the transfection value chain. In the immediate aftermath, many laboratories and organizations revisited sourcing strategies to mitigate near-term cost increases, prioritizing suppliers with diversified manufacturing footprints or those able to offer localized inventory buffers. These adjustments often involved renegotiating terms, consolidating orders to preserve pricing, and working more closely with distributors to maintain continuity of supply.

Over a longer horizon, tariffs have accelerated conversations about onshoring critical production and increasing supplier redundancy. Firms with the operational agility to reallocate production or to shift component sourcing have been better positioned to protect experimental continuity. At the same time, smaller academic and research institutions have faced more acute budgetary pressure, prompting procurement teams to seek multi-use reagents and instrumentation that deliver broader utility across projects. Importantly, tariffs have magnified the strategic importance of supply chain transparency and supplier risk assessment, encouraging organizations to invest in vendor qualification and inventory planning to sustain R&D pipelines under evolving trade conditions.

Key segmentation insights across product types, cell types, applications, and end users revealing nuanced demand drivers and procurement behaviors

Segmentation-driven insights reveal differentiated demand patterns and operational requirements across product types, cell types, applications, and end users. Based on Product Type, the market is studied across Equipment and Reagents, with equipment purchases increasingly influenced by compatibility with automation systems and data integration, while reagents are evaluated for formulation stability and cross-platform performance. Based on Cell Type, the market is studied across Bacterial Cells, Insect Cells, Mammalian Cells, and Plant Cells, and each category exhibits distinct transfection sensitivities, throughput needs, and validation challenges that influence reagent selection and protocol development.

Based on Application, the market is studied across Cell Line Development, Drug Discovery, and Gene Therapy Research, with cell line development demanding reproducibility and scale-up pathways, drug discovery emphasizing throughput and assay compatibility, and gene therapy research prioritizing delivery efficiency and regulatory-grade documentation. Based on End User, the market is studied across Academic And Research Institutes, Biopharmaceutical Companies, and Contract Research Organizations, where academic labs often prioritize flexibility and cost-effectiveness, biopharma focuses on qualification and portability to clinical pipelines, and CROs require broad reagent and equipment portfolios to service diverse client needs. Collectively, these segmentation perspectives underscore the importance of tailored value propositions, validated workflows, and service models that address the specific technical and commercial drivers inherent to each category.

Regional dynamics and competitive positioning across the Americas, Europe Middle East & Africa, and Asia-Pacific informing market entry and partnership strategies

Regional dynamics are shaping competitive positioning and go-to-market strategies across major geographies. In the Americas, investment in biopharmaceutical R&D, coupled with a strong presence of contract research organizations and advanced academic centers, drives demand for high-performance reagents and integrated instruments that support translational pipelines. Market participants in this region often prioritize regulatory alignment, vendor transparency, and partnership models that can accelerate clinical translation.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory frameworks and funding models vary widely, creating both opportunities and complexity. In these markets, suppliers benefit from localized validation data and collaborative partnerships with regional research consortia. Europe in particular emphasizes reproducibility and quality management systems, while several Middle Eastern and African centers are investing in capacity building and infrastructure modernization. Asia-Pacific is characterized by rapid expansion in life science R&D capability, government-led initiatives to support biotechnology, and a growing manufacturing base. Suppliers operating in Asia-Pacific are increasingly localizing production and offering scalable solutions that cater to a broad range of end users, from emerging academic centers to large domestic biopharma firms. Understanding these regional nuances is essential for prioritizing market entry tactics, distribution strategies, and localized service offerings.

Strategic profiles and capability analysis of leading companies shaping transfection reagents and equipment through R&D, partnerships, and platform expansion

Leading companies in the space are differentiating through a combination of R&D investment, strategic partnerships, and expanding platform capabilities. Some firms are concentrating on reagent chemistry optimization to enhance delivery efficiency and reduce cytotoxicity across challenging cell types, while others are integrating hardware, software, and consumables to deliver turnkey solutions that lower the barrier to adoption. Collaborations between reagent developers and instrument manufacturers are becoming more common, as are partnerships with academic labs and contract research organizations to validate workflows across diverse applications.

Corporate strategies also reflect an emphasis on regulatory readiness and quality systems that support translational use cases. Companies that proactively generate comprehensive validation data and provide robust technical support are establishing credibility with biopharmaceutical customers and CROs. Additionally, several firms are exploring modular business models, combining direct sales with channel partnerships and subscription services for consumables and software. These approaches enhance customer lifetime value and create recurring revenue streams while enabling more predictable supply and service delivery for critical R&D activities.

Actionable recommendations for industry leaders to accelerate adoption, optimize supply chains, and capture value across diverse transfection market segments

Industry leaders should adopt a set of pragmatic actions to accelerate adoption, strengthen supply chains, and capture strategic value across segments. First, invest in creating validated, cross-platform protocols and comprehensive application notes that demonstrate performance across the primary cell types and use cases. This evidence base reduces adoption friction and supports procurement decisions across academic, biopharma, and CRO customers. Second, diversify manufacturing and logistics footprints to mitigate trade and tariff risks while ensuring continuity of supply for critical reagents and instrument components.

Third, pursue strategic alliances with technology partners and end users to co-develop solutions tailored to high-value applications such as gene therapy and complex cell line development. Fourth, enhance commercial models by combining equipment sales with consumable subscriptions and managed services that provide predictable revenue and deeper customer engagement. Finally, strengthen technical service and training offerings to support reproducibility and to facilitate rapid scale-up from discovery to translational stages. Together, these actions will help suppliers align product development and go-to-market execution with evolving customer expectations and regulatory requirements.

Research methodology detailing data sources, stakeholder interviews, primary and secondary research integration, and analytical frameworks ensuring rigor

The research methodology underpinning this analysis integrates primary interviews, secondary data synthesis, and cross-validated expert review to ensure analytical rigor and relevance. Primary research included structured interviews with laboratory directors, procurement managers, R&D scientists, and commercial leaders across a representative set of academic institutions, biopharmaceutical companies, and contract research organizations. These conversations provided direct insight into procurement drivers, performance pain points, and validation priorities.

Secondary research involved a systematic review of peer-reviewed literature, regulatory guidance, patent filings, and technical white papers to contextualize technological trends and to verify product claims. Data triangulation was applied to reconcile divergent inputs and to surface consistent patterns across geographies and end-user types. Analytical frameworks used in the study include value chain mapping, supplier capability assessment, and scenario-based sensitivity analysis to explore the impacts of supply disruption and regulatory change. Throughout, subject matter experts provided iterative review to refine interpretations and to ensure that findings are actionable for decision-makers.

Conclusion synthesizing strategic implications, risk considerations, and priority actions for stakeholders navigating the transfection ecosystem

In conclusion, the transfection reagents and equipment ecosystem is advancing at the intersection of innovation, regulatory expectation, and shifting procurement behaviors. Technological progress in delivery chemistries, automation, and integration with gene editing platforms is expanding the range of tractable applications while raising the bar for reproducibility and quality assurance. At the same time, trade dynamics and evolving regional capabilities are reshaping supply chain strategies and commercial approaches.

Stakeholders should prioritize resilience, validated performance, and customer-centric service models to capture emerging opportunities. For product developers, the imperative is to align R&D investment with the specific needs of diverse cell types and application areas. For end users, building robust vendor qualification and inventory management practices will protect continuity of research. As the field evolves, coordinated partnerships among suppliers, customers, and regulatory bodies will be critical to translate technological potential into clinical and commercial outcomes. The synthesis offered here provides a strategic foundation for informed decision-making and targeted action in this dynamic sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transfection Reagents & Equipment Market, by Product Type

  • 8.1. Equipment
  • 8.2. Reagents

9. Transfection Reagents & Equipment Market, by Cell Type

  • 9.1. Bacterial Cells
  • 9.2. Insect Cells
  • 9.3. Mammalian Cells
  • 9.4. Plant Cells

10. Transfection Reagents & Equipment Market, by Application

  • 10.1. Cell Line Development
  • 10.2. Drug Discovery
  • 10.3. Gene Therapy Research

11. Transfection Reagents & Equipment Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Biopharmaceutical Companies
  • 11.3. Contract Research Organizations

12. Transfection Reagents & Equipment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Transfection Reagents & Equipment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Transfection Reagents & Equipment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Transfection Reagents & Equipment Market

16. China Transfection Reagents & Equipment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Altogen Biosystems
  • 17.7. Applied Biological Materials, Inc.
  • 17.8. Bex Co.,ltd.
  • 17.9. BioVision Inc.
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. Cytiva
  • 17.12. GeneCopoeia, Inc.
  • 17.13. Lonza Group AG
  • 17.14. Qiagen N.V.
  • 17.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY BACTERIAL CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY BACTERIAL CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY BACTERIAL CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY INSECT CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY INSECT CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY INSECT CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY MAMMALIAN CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY MAMMALIAN CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY MAMMALIAN CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PLANT CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PLANT CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PLANT CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY GENE THERAPY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY GENE THERAPY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY GENE THERAPY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GCC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. GCC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. GCC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. GCC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. G7 TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. G7 TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. G7 TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. G7 TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NATO TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NATO TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NATO TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NATO TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)